Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Bidard, François‐Clément; Hardy‐Bessard, Anne‐Claire; Dalenc, Florence; Bachelot, Thomas; Pierga, Jean‐Yves; Rouge, Thibault de la Motte; Sabatier, Renaud; Dubot, Coraline; Frenel, Jean‐Sébastien; Ferrero, Jean Marc; Ladoire, Sylvain; Levy, Christelle; Mouret‐Reynier, Marie‐Ange; Lortholary, Alain; Grenier, Julien; Chakiba, Camille; Stefani, Laëtitia; Plaza, Jérôme Edouard; Clatot, Florian; Teixeira, Luís; D'Hondt, Véronique; Vegas, Hélène; Derbel, Olfa; Garnier-Tixidré, Claire; Canon, Jean-Luc; Pistilli, Barbara; André, Fabrice; Arnould, Laurent; Pradines, Anne; Bièche, Ivan; Callens, Céline; Lemonnier, Jérôme; Berger, Frédérique; Delaloge, Suzette; Bidard, François‐Clément; Pistilli, Barbara; Dalenc, Florence; BACHELOT, Thomas; ROUGE, Thibault DE LA MOTTE; SABATIER, Renaud; Dubot, Coraline; Frenel, Jean‐Sébastien; Ferrero, Jean-­Marc; Ladoire, Sylvain; LEVY, Christelle; Mouret‐Reynier, Marie‐Ange; Hardy‐Bessard, Anne‐Claire; Lortholary, Alain; GRENIER, Julien; Chakiba, Camille; Stefani, Laëtitia; Soulié, P; Jacquin, Jean-Philippe; Plaza, Jérôme Edouard; Clatot, Florian; Teixeira, Luís; D'HONDT, Véronique; VEGAS, Hélène; Derbel, Olfa; Tixidre, Claire Garnier; Delbaldo, Catherine; MOREAU, Lionel; Cheneau, Caroline; Paitel, Jean-François; BERNARD-MARTY, Chantal; Spaëth, Dominique; Genet, Dominique; MOULLET, Isabelle; BONICHON-LAMICHHANE, Nathalie; DEIANA, Laura; GREILSAMER, Charlotte; Venat‐Bouvet, Laurence; Delecroix, Valérie; MELIS, Adrien; Orfeuvre, Hubert; Nguyen, Suzanne; Legouffe, Éric; Zannetti, Alain; Scodan, Romuald Le; Dohollou, Nadine; DALIVOUST, Philippe; Arsène, Olivier; MARQUES, Nathalie; Petit, Thierry; MOLLON, Delphine; Dauba, Jérôme; Bonnin, Nathalie; MORVAN, François; Gardner, Miriam; MARTI, Adina; Levaché, Charles-Briac; Lachaier, Emma; ACHILLE, Mihaela; VALMAR, Christophe; Bouaita, Ryan; Médioni, Jacques; Foa, Cyril; BERNARD-MARTY, Chantal; Piano, Francesco Del; GOZY, Michel; Escande, Anne; Leduc, Nicolas; LUCAS, Brigitte; Mille, Dominique; Ammarguellat, Hanifa; NAJEM, Abeer; TROUBOUL, Fanny; Barthélémy, Philippe; DESCLOS, Hervé; Mayeur, Didier; LORCHEL, Fabrice; GUINET, François; Laurenty, Anne-Pascale; BOUDRANT, Axelle; GISSEROT, Olivier; ALLEAUME, Corinne; Gramont, Aimery de

doi:10.1016/s1470-2045(22)00555-1

articleThe Lancet OncologySep 29, 2022Closed access

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

FBFrançois‐Clément Bidard AHAnne‐Claire Hardy‐Bessard FDFlorence DalencTBThomas BachelotJPJean‐Yves Pierga

Inserm · Université Paris-Saclay · +30 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

307

total citations

FWCI: 42.91
Percentile: 100%
References: 16

Citations per year

Authors

117

FB
François‐Clément BidardCorresponding
Inserm, Université Paris-Saclay, Institut Curie
AH
Anne‐Claire Hardy‐Bessard
FD
Florence Dalenc
Institut Claudius Regaud
TB
Thomas Bachelot
Centre Léon Bérard
JP
Jean‐Yves Pierga
Inserm, Institut Curie

Topics & keywords

Topics

Keywords

Palbociclib
Fulvestrant
Exemestane
Medicine
Letrozole
Aromatase inhibitor
Anastrozole
Breast cancer

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.